Susquehanna International Group’s MABVAX THERAPEUTICS HLDGS INC MBVX Stock Holding History

Susquehanna International Group’s Portfolio MBVX Stock Details MBVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-75,904	Closed	-$65K	–	10898
2018 Q2	$65K	Buy	+75,904	New	+$96.2K	﹤0.01%	9200
2017 Q4	–	Sell	-10,266	Closed	-$20K	–	10314
2017 Q3	$20K	Buy	+10,266	New	+$22.5K	﹤0.01%	8650

Other funds holding MBVX

PAM

Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

BCM

Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return

Susquehanna International Group's MBVX Position: Q3 2018 in Review

Susquehanna International Group sold out of MABVAX THERAPEUTICS HLDGS INC (MBVX) in Q3 2018, closing a stake of 75,904 shares — an estimated $65K sold.

Susquehanna International Group first reported a position in MBVX in Q3 2017 and held it in 2 quarters. The position peaked at $65K in Q2 2018. 2 funds tracked by Wall St. Rank hold MBVX as of Q3 2018.

Susquehanna International Group reported no remaining MABVAX THERAPEUTICS HLDGS INC position as of Q3 2018 after selling out during the quarter.
Susquehanna International Group sold 75,904 MABVAX THERAPEUTICS HLDGS INC shares in Q3 2018, an estimated $65K.
Susquehanna International Group first reported a position in MABVAX THERAPEUTICS HLDGS INC in Q3 2017 and held it in 2 quarters.
Susquehanna International Group's MABVAX THERAPEUTICS HLDGS INC position peaked at $65K in Q2 2018.
2 funds tracked by Wall St. Rank held MABVAX THERAPEUTICS HLDGS INC as of Q3 2018.

Based on Susquehanna International Group's 13F filing for Q3 2018, filed 14 Nov 2018.